The DCI-Designated Program in Cancer Genetics and Genomics (CGG) program was re-organized in 2012 by merging two pre-existing programs and recruiting new faculty around the central themes of cancer genetics, epigenetics, gene expression, and genomics. The goals of the Program are to coordinate the Duke Cancer Institute research activities related to the aforementioned themes and to inform the application of 'omics' technologies that assess alterations in cancer genomes, epigenomes and transcriptomes. This interactive and integrated program is organized into three Focus Groups: (1) Epigenetics and Epigenomics, (2) DNA Replication, Recombination and Repair, and (3) Gene Expression (which includes viral oncology). The Program includes 35 p r i m a r y members from 18 basic and clinical departments within Duke University School of Medicine and the School of Engineering and 28 secondary members. Total funding (Direct + Indirect) for program members was $23.5M in 2013, of which $18M came from peer-reviewed sources. A cancer-focus was illustrated by $3.6M from the NCI, the American Cancer Society, or cancer-related Department of Defense programs. From 2009-2013, program members published 640 papers in peer- reviewed journals cited in PubMed. Of these publications, 4.6% were the result of intra-programmatic collaborations, 18% due to inter-programmatic collaborations, and 1.8% both. Note: Although it shares the same name as a program in existence at the time of the previous competitive renewal, CGG is essentially a new program started in 2012.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-44
Application #
9404312
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications